14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
OTLK vs CSBR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Outlook Therapeutics, Inc. (OTLK) is the stronger overall head-to-head candidate over Champions Oncology, Inc. (CSBR) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). OTLK carries a Unified Composite Score of 48.6/100 (HOLD) at $0.40 (2.9x Forward P/E, 4781.8% operating margin), whereas CSBR carries 42.9/100 (HOLD) at $4.71 (47.0x Forward P/E, -1.5% operating margin).
Growth vs. Quality Trade-Off: OTLK earns the overall head-to-head edge with a stronger Unified Composite Score (48.6/100 HOLD vs. CSBR 42.9/100 HOLD) and 1.47β · 79% Vol risk profile, whereas CSBR leads top-line expansion (+8.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: OTLK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.2); meanwhile CSBR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OTLK vs CSBR. Trailing 12-month operating profitability (OTLK 4781.8% vs CSBR -1.5%) and valuation multiples (OTLK 2.9x vs CSBR 47.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $64.7M market capitalization and -1.5% operating margin.
OpEx & R&D Reinvestment51.3% of Rev ($31M)
90D Engineering Disclosures0 Published
Investor FAQ OTLK vs CSBR Key Questions & Quantitative Answers
As of Nov 16, 2026, Outlook Therapeutics, Inc. (OTLK) is the stronger overall head-to-head candidate over Champions Oncology, Inc. (CSBR) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). OTLK carries a Unified Composite Score of 48.6/100 (HOLD) at $0.40 (2.9x Forward P/E, 4781.8% operating margin), whereas CSBR carries 42.9/100 (HOLD) at $4.71 (47.0x Forward P/E, -1.5% operating margin). Growth vs. Quality Trade-Off: OTLK earns the overall head-to-head edge with a stronger Unified Composite Score (48.6/100 HOLD vs. CSBR 42.9/100 HOLD) and 1.47β · 79% Vol risk profile, whereas CSBR leads top-line expansion (+8.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: OTLK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.2); meanwhile CSBR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CSBR leads the Growth & Scale pillar: OTLK posts -99.4% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 4781.8% operating margin), compared with CSBR at +8.8% YoY revenue growth and -61.1% YoY earnings growth on $61M TTM revenue (49.8% gross margin, -1.5% operating margin). On trailing 12-month operating scale, OTLK generates N/A in USD-normalized revenue versus $61M for CSBR. In operating R&D and SG&A reinvestment, OTLK deploys N/A (0 90-day corporate R&D disclosures) versus 51.3% of Rev ($31M) (0 disclosures) for CSBR.
OTLK screens cheaper on headline valuation multiples. OTLK trades at 2.9x Forward P/E, 2.9x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CSBR trades at 47.0x Forward P/E, 22.9x Trailing P/E, N/M PEG, and 1.1x EV/Revenue (0.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OTLK (-3.6% ROE) versus CSBR (-28.4% ROE) capital efficiency.
In options market volatility and institutional positioning, OTLK carries 181.3% implied volatility (55th %ile, Balanced (25th–60th %ile)), a 0.26x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.47β · 79% Vol realized risk). By comparison, CSBR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.36β · 24% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.